Craig-Hallum analyst Chase Knickerbocker lowered the firm’s price target on Delcath Systems (DCTH) to $20 from $24 and keeps a Buy rating on the shares following the company’s prerelease/guidance and CHOPIN data at ESMO. Phase 2 CHOPIN study data presented at ESMO showed a clear benefit for Chemosat/Hepzato combined with checkpoint inhibitors in metastatic uveal melanoma. However, this news was overshadowed by disappointing Q3 and FY25 guidance, with Q3 revenue guided to $20.5M and FY25 revenue to $83M-$85M, the firm says. Craig-Hallum expects the CHOPIN data to inform U.S. use of Hepzato in sequence with checkpoint inhibitors, potentially driving increased volume in the second half of 2026.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DCTH:
- Promising CHOPIN Data and Strategic Developments Support Delcath Systems’ Buy Rating
- Clear Street ups Delcath target, sees opportunity on selloff
- Delcath Systems reports preliminary Q3 adjusted EBITDA $4.8M
- Delcath Systems price target lowered to $30 from $31 at H.C. Wainwright
- Delcath Systems: Promising Growth Potential Amidst Challenges with Strong Buy Rating